Clinical Trial Update: Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating Boserolimab (MK-5890) alone and in combination with Pembrolizumab (MK-3475) in adults with advanced solid tumors; trial completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Boserolimab (boserolimab)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pharmacokinetics, Solid Tumor | Phase 1 | Status: COMPLETED | Results posted: 2025-11-05